Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
ABSTRACT Inhalational anthrax caused by Bacillus anthracis, a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evide...
Guardado en:
Autores principales: | Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bbcf90b9c4804021a29a4fed189b8a61 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen
por: Anita Verma, et al.
Publicado: (2018) -
Detecting specific memory t and b cells in volunteers annually revaccinated with live anthrax vaccine
por: V. V. Firstova, et al.
Publicado: (2019) -
COMPLIANCE OF ANTHRAX RECOMBINANT VACCINE PROTOTYPE WITH THE REQUIREMENTS TO IMMUNE-BIOLOGICAL PREPARATIONS
por: N. I. Mikshis, et al.
Publicado: (2018) -
Using CAST-test to investigate human specific hypersensitivity to the anthrax pathogen
por: D. G. Ponomarenko, et al.
Publicado: (2020) -
Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice
por: Fabiana Freire Mendes de Oliveira, et al.
Publicado: (2020)